Hernández-García Ignacio, Rodríguez-Montolio Joana, Almeida-Zurita Monserrath, Cheli-Gracia Dionisio, Sahuquillo Belén Del Moral, Aibar-Remón Carlos, Garcés-Redondo Moisés
Department of Preventive Medicine and Public Health, Lozano Blesa University Clinical Hospital of Zaragoza, Calle San Juan Bosco 15, 50009 Zaragoza, Spain.
Health Services Research Group of Aragon (GRISSA), Aragon Institute for Health Research (IISA), Calle San Juan Bosco 15, 50009 Zaragoza, Spain.
Vaccines (Basel). 2024 Jan 26;12(2):126. doi: 10.3390/vaccines12020126.
Our objective was to know the COVID-19 vaccination coverage in multiple sclerosis (MS) patients and its factors associated. A retrospective cohort study was carried out. Patients seen at the MS unit of the University Clinical Hospital of Zaragoza between 2017 and 2021 were included. Variables were obtained by reviewing the specialized and primary care records. Associations between receiving COVID-19 full primo-vaccination, as well as one booster dose since autumn 2022, and the other variables were analyzed using bivariate analysis and multiple logistic regression models. Of the 359 included patients, 90.3% received the COVID-19 full primo-vaccination. Having been born in Spain (OR = 3.40) and having received the 2020-2021 influenza vaccine (OR = 6.77) were associated with receiving the COVID-19 full primo-vaccination. Vaccination with a COVID-19 booster dose was detected in 141 patients (39.3%). Sex (man) (OR = 2.36), age (60 years or over) (OR = 6.82), type of MS (Primary Progressive/Secondary Progressive) (OR = 3.94), and having received the 2022-2023 influenza vaccine (OR = 27.54) were associated with receiving such a booster dose. The COVID-19 booster dose was administered at the same time as the 2022-2023 influenza vaccine in 57.8% (67/116) of the patients vaccinated with both vaccines. The COVID-19 full primo-vaccination coverage is higher than in other countries. However, the decrease in vaccination coverage with the booster dose makes it necessary to develop strategies to improve it that are not limited to administering the flu vaccine together with the COVID-19 booster dose. Such strategies should be in focus, especially for women under 60 years of age.
我们的目标是了解多发性硬化症（MS）患者的新冠疫苗接种覆盖率及其相关因素。开展了一项回顾性队列研究。纳入了2017年至2021年期间在萨拉戈萨大学临床医院MS科室就诊的患者。通过查阅专科和初级保健记录获取变量。使用双变量分析和多元逻辑回归模型分析接受新冠完整初种疫苗以及自2022年秋季以来接受一剂加强针与其他变量之间的关联。在纳入的359例患者中，90.3%接受了新冠完整初种疫苗。出生在西班牙（比值比[OR]=3.40）以及接种了2020 - 2021年流感疫苗（OR = 6.77）与接受新冠完整初种疫苗相关。141例患者（39.3%）接种了新冠加强针。性别（男性）（OR = 2.36）、年龄（60岁及以上）（OR = 6.82）、MS类型（原发进展型/继发进展型）（OR = 3.94）以及接种了2022 - 2023年流感疫苗（OR = 27.54）与接受这种加强针相关。在同时接种两种疫苗的患者中，57.8%（67/116）的患者在接种2022 - 2023年流感疫苗的同时接种了新冠加强针。新冠完整初种疫苗的接种覆盖率高于其他国家。然而，加强针接种覆盖率的下降使得有必要制定策略来提高覆盖率，这些策略不应局限于将流感疫苗与新冠加强针同时接种。此类策略应成为重点，尤其是对于60岁以下的女性。
